The global myelodysplastic syndrome treatment market is poised to register a 5.9% CAGR, capturing a revenue share of USD 2,990.8 million in 2022, to reach USD 5,614.1 million by 2032.
| Report Attribute | Details |
|---|---|
| Myelodysplastic Syndrome Treatment Market Value (2022) | USD 2,990.8 Million |
| Myelodysplastic Syndrome Treatment Market Anticipated Forecast Value (2032) | USD 5,614.1 Million |
| Myelodysplastic Syndrome Treatment Market Projected Growth Rate (2022 to 2032) | 5.9% |
The rising adoption of myelodysplastic syndrome treatment can be attributed to new drugs and drug combinations that may work better and have less severe side effects that are the subject of studies.
Currently, the myelodysplastic syndrome treatment market trends are shaped by some of the most effective medications for treating MDS, classified as hypomethylating agents, such as azacitidine (Vidaza) and decitabine (Dacogen).
In the USA, myelodysplastic syndromes (MDS) occur at a rate of 4.8 cases for every 100,000 people, positively impacting the myelodysplastic syndrome treatment adoption trends.
In addition to this, the adoption of myelodysplastic syndrome treatment is on the surge as the number of new cases diagnosed each year seems to be increasing as the average age of the population increases. (Source: American Cancer Society).
Furthermore, diagnosis techniques such as blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS, leading to the demand for myelodysplastic syndrome treatment.
The myelodysplastic syndrome treatment market size is expected to expand to a significant extent in the coming few years due to increasing mutation in treatments, which cause myelodysplastic syndrome.
Moreover, growing number of patient pool of age 50 and above, and rising government support for cancer treatment augurs well for the myelodysplastic syndrome treatment market future trends.
However, unawareness about such treatments is one of the major factors mitigating the demand for myelodysplastic syndrome treatment.
The complexity and clonal heterogeneity of MDS also pose a challenge to the myelodysplastic syndrome treatment growth as it is frequently unknown, which mutations are early initiating events and are later events that only affect a subclone.
Despite these concerns, researchers are currently testing a number of strategies to try to enhance existing MDS therapeutics, in turn, create numerous myelodysplastic syndrome treatment market opportunities.
One of such myelodysplastic syndrome treatment market trends is the combination therapies that have either additive or synergistic effects in vitro.
Higher response rates than those seen with either drug alone may be possible when azacitidine is combined with lenalidomide or vorinostat (a deacetylase inhibitor currently FDA approved for treating cutaneous T-cell lymphoma).
The myelodysplastic syndrome treatment market outlook is to be swayed by a cooperative group trial in the United States and Canada that are currently investigating whether these combinations will improve patient outcomes in comparison to azacitidine monotherapy.
Due to the rising healthcare costs, and rising end-user demand for myelodysplastic syndrome treatment, North America is anticipated to control a myelodysplastic syndrome treatment market share of 34.6% in 2022.
And as the growth is further fostered by the focus of major players and non-profit organisations present on launching new initiatives and public awareness campaigns to inform people about gout disease and support medical professionals.
A growing awareness of MDS among Americans is expected to cause the USA to expand the myelodysplastic syndrome treatment market size over the forecast period.
Europe is predicted to experience significant growth and hold a market share of 31.1% in 2022 due to an increase in governmental initiatives for disease diagnosis and treatment.
As an illustration, the European LeukemiaNet WP8 promoted a programme with the goal of creating and regularly updating evidence- and consensus-based guidelines to provide clinical practise recommendations for standardised diagnostic and prognostic procedures and for an appropriate choice of therapeutic interventions in adult patients with primary MDS.
A significant factor that is anticipated to propel the myelodysplastic syndrome treatment market share of Europe is the increasing efforts made by pharmaceutical companies to introduce highly effective therapies for MDS.
The oral medication tamibarotene from Syros Pharmaceuticals has been given orphan drug designation (ODD) by the USA Food and Drug Administration (FDA) to treat myelodysplastic syndrome (MDS).
A selective retinoic acid receptor alpha (RAR) agonist is tamibarotene.
In the Phase III SELECT-MDS-1 clinical trial, oral therapy is currently being evaluated in addition to azacitidine to treat RARA-positive patients with recently discovered higher-risk MDS (HR-MDS).
The effectiveness and safety of the combination therapy are being evaluated in this ongoing trial.
The pivotal trial's results are expected by the company in the fourth quarter of 2019 or the first quarter of 2024.
In 2024, Syros also intends to submit a potential new drug application.
The myelodysplastic syndrome treatment market is consolidated with a presence of few strong players from around the globe.
Some of the players identified in global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Holdings Co., Ltd., Sandoz, Inc., Dr. Reddy's Laboratories, Inc., Accord Healthcare Ltd., Mylan N.V., Pfizer, Inc. etc.
Emerging trends in myelodysplastic syndrome treatment market are brought about as a result of the major players' adoption of several growth strategies, including product launches, acquisitions, and collaborations.
Some of the recent developments in the myelodysplastic syndrome treatment market are as follows:
Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL).
| Report Attribute | Details |
|---|---|
|
Growth Rate |
CAGR of 5.9% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2014 to 2020 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
Type, Treatment, Patient Group, Region |
|
Regions Covered |
North America; Latin America; Western Europe; Eastern Europe; Asia Pacific excluding Japan; Japan; The Middle East and Africa |
|
Key Countries Profiled |
USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
|
Key Companies Profiled |
Celgene Corporation; Otsuka Holdings Co., Ltd.; Sandoz, Inc.; Dr. Reddy's Laboratories, Inc.; Accord Healthcare Ltd.; Mylan N.V.; Pfizer, Inc. |
|
Customization |
Available Upon Request |
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Market Value (US$ Mn) Forecast by Type, 2017-2032
Table 3: Global Market Value (US$ Mn) Forecast by Treatment, 2017-2032
Table 4: Global Market Value (US$ Mn) Forecast by Patient Group, 2017-2032
Table 5: North America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Market Value (US$ Mn) Forecast by Type, 2017-2032
Table 7: North America Market Value (US$ Mn) Forecast by Treatment, 2017-2032
Table 8: North America Market Value (US$ Mn) Forecast by Patient Group, 2017-2032
Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Market Value (US$ Mn) Forecast by Type, 2017-2032
Table 11: Latin America Market Value (US$ Mn) Forecast by Treatment, 2017-2032
Table 12: Latin America Market Value (US$ Mn) Forecast by Patient Group, 2017-2032
Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Market Value (US$ Mn) Forecast by Type, 2017-2032
Table 15: Europe Market Value (US$ Mn) Forecast by Treatment, 2017-2032
Table 16: Europe Market Value (US$ Mn) Forecast by Patient Group, 2017-2032
Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Type, 2017-2032
Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Treatment, 2017-2032
Table 20: Asia Pacific Market Value (US$ Mn) Forecast by Patient Group, 2017-2032
Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: MEA Market Value (US$ Mn) Forecast by Type, 2017-2032
Table 23: MEA Market Value (US$ Mn) Forecast by Treatment, 2017-2032
Table 24: MEA Market Value (US$ Mn) Forecast by Patient Group, 2017-2032
Figure 1: Global Market Value (US$ Mn) by Type, 2022-2032
Figure 2: Global Market Value (US$ Mn) by Treatment, 2022-2032
Figure 3: Global Market Value (US$ Mn) by Patient Group, 2022-2032
Figure 4: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Market Value (US$ Mn) Analysis by Type, 2017-2032
Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2022-2032
Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2022-2032
Figure 11: Global Market Value (US$ Mn) Analysis by Treatment, 2017-2032
Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2022-2032
Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032
Figure 14: Global Market Value (US$ Mn) Analysis by Patient Group, 2017-2032
Figure 15: Global Market Value Share (%) and BPS Analysis by Patient Group, 2022-2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by Patient Group, 2022-2032
Figure 17: Global Market Attractiveness by Type, 2022-2032
Figure 18: Global Market Attractiveness by Treatment, 2022-2032
Figure 19: Global Market Attractiveness by Patient Group, 2022-2032
Figure 20: Global Market Attractiveness by Region, 2022-2032
Figure 21: North America Market Value (US$ Mn) by Type, 2022-2032
Figure 22: North America Market Value (US$ Mn) by Treatment, 2022-2032
Figure 23: North America Market Value (US$ Mn) by Patient Group, 2022-2032
Figure 24: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Market Value (US$ Mn) Analysis by Type, 2017-2032
Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2022-2032
Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2022-2032
Figure 31: North America Market Value (US$ Mn) Analysis by Treatment, 2017-2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2022-2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032
Figure 34: North America Market Value (US$ Mn) Analysis by Patient Group, 2017-2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Patient Group, 2022-2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Patient Group, 2022-2032
Figure 37: North America Market Attractiveness by Type, 2022-2032
Figure 38: North America Market Attractiveness by Treatment, 2022-2032
Figure 39: North America Market Attractiveness by Patient Group, 2022-2032
Figure 40: North America Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Market Value (US$ Mn) by Type, 2022-2032
Figure 42: Latin America Market Value (US$ Mn) by Treatment, 2022-2032
Figure 43: Latin America Market Value (US$ Mn) by Patient Group, 2022-2032
Figure 44: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Market Value (US$ Mn) Analysis by Type, 2017-2032
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2022-2032
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2022-2032
Figure 51: Latin America Market Value (US$ Mn) Analysis by Treatment, 2017-2032
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2022-2032
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032
Figure 54: Latin America Market Value (US$ Mn) Analysis by Patient Group, 2017-2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Patient Group, 2022-2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Patient Group, 2022-2032
Figure 57: Latin America Market Attractiveness by Type, 2022-2032
Figure 58: Latin America Market Attractiveness by Treatment, 2022-2032
Figure 59: Latin America Market Attractiveness by Patient Group, 2022-2032
Figure 60: Latin America Market Attractiveness by Country, 2022-2032
Figure 61: Europe Market Value (US$ Mn) by Type, 2022-2032
Figure 62: Europe Market Value (US$ Mn) by Treatment, 2022-2032
Figure 63: Europe Market Value (US$ Mn) by Patient Group, 2022-2032
Figure 64: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Market Value (US$ Mn) Analysis by Type, 2017-2032
Figure 69: Europe Market Value Share (%) and BPS Analysis by Type, 2022-2032
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Type, 2022-2032
Figure 71: Europe Market Value (US$ Mn) Analysis by Treatment, 2017-2032
Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2022-2032
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032
Figure 74: Europe Market Value (US$ Mn) Analysis by Patient Group, 2017-2032
Figure 75: Europe Market Value Share (%) and BPS Analysis by Patient Group, 2022-2032
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Patient Group, 2022-2032
Figure 77: Europe Market Attractiveness by Type, 2022-2032
Figure 78: Europe Market Attractiveness by Treatment, 2022-2032
Figure 79: Europe Market Attractiveness by Patient Group, 2022-2032
Figure 80: Europe Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Market Value (US$ Mn) by Type, 2022-2032
Figure 82: Asia Pacific Market Value (US$ Mn) by Treatment, 2022-2032
Figure 83: Asia Pacific Market Value (US$ Mn) by Patient Group, 2022-2032
Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Type, 2017-2032
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2022-2032
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2022-2032
Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Treatment, 2017-2032
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2022-2032
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032
Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by Patient Group, 2017-2032
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Patient Group, 2022-2032
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Patient Group, 2022-2032
Figure 97: Asia Pacific Market Attractiveness by Type, 2022-2032
Figure 98: Asia Pacific Market Attractiveness by Treatment, 2022-2032
Figure 99: Asia Pacific Market Attractiveness by Patient Group, 2022-2032
Figure 100: Asia Pacific Market Attractiveness by Country, 2022-2032
Figure 101: MEA Market Value (US$ Mn) by Type, 2022-2032
Figure 102: MEA Market Value (US$ Mn) by Treatment, 2022-2032
Figure 103: MEA Market Value (US$ Mn) by Patient Group, 2022-2032
Figure 104: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Market Value (US$ Mn) Analysis by Type, 2017-2032
Figure 109: MEA Market Value Share (%) and BPS Analysis by Type, 2022-2032
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Type, 2022-2032
Figure 111: MEA Market Value (US$ Mn) Analysis by Treatment, 2017-2032
Figure 112: MEA Market Value Share (%) and BPS Analysis by Treatment, 2022-2032
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2022-2032
Figure 114: MEA Market Value (US$ Mn) Analysis by Patient Group, 2017-2032
Figure 115: MEA Market Value Share (%) and BPS Analysis by Patient Group, 2022-2032
Figure 116: MEA Market Y-o-Y Growth (%) Projections by Patient Group, 2022-2032
Figure 117: MEA Market Attractiveness by Type, 2022-2032
Figure 118: MEA Market Attractiveness by Treatment, 2022-2032
Figure 119: MEA Market Attractiveness by Patient Group, 2022-2032
Figure 120: MEA Market Attractiveness by Country, 2022-2032
The global myelodysplastic syndrome treatment market is set to advance at a CAGR of 5.9% from 2022 to 2032.
North America is likely to hold a myelodysplastic syndrome treatment market share of 34.6% in 2022.
The myelodysplastic syndrome treatment market is likely to account for USD 5,614.1 million by 2032.
Explore Similar Insights
Myelodysplastic Syndrome Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
